Mounjaro and Zepbound are the same drug: tirzepatide manufactured by Eli Lilly. The pens are identical. The doses are identical. The molecule is identical. What differs is the FDA-approved indication, Mounjaro for type 2 diabetes, Zepbound for chronic weight management, and therefore what a prescriber must document to write the prescription, and what insurance will cover.
This regulatory parallel mirrors the Ozempic-Wegovy situation with semaglutide, and the practical consequences for patients are similar.
The Regulatory History
The FDA approved Mounjaro in May 2022 for type 2 diabetes management. The approval was based on the SURPASS trial program, which demonstrated substantial blood sugar reduction and, as a secondary outcome, significant weight loss.
The FDA approved Zepbound in November 2023 for chronic weight management in adults with BMI 30 or above, or BMI 27 or above with at least one weight-related comorbidity. The approval was based on the SURMOUNT trial program, particularly SURMOUNT-1, which enrolled adults without diabetes and confirmed tirzepatide’s weight loss efficacy as a primary endpoint.
Both approvals cover tirzepatide in doses of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg weekly, a six-step escalation identical across both brand names.
Why the Same Drug Has Two Brand Names
FDA approval is indication-specific. A drug company must submit separate applications demonstrating safety and efficacy for each indication it seeks approval for. Eli Lilly chose to market tirzepatide under two brand names for commercial and regulatory clarity, Mounjaro positioned in the diabetes market, Zepbound in the obesity market.
From a clinical perspective, there is no pharmacological distinction between the two products.
Insurance and Coverage Implications
The consequences of the dual-brand structure are practical:
Patients with type 2 diabetes: Mounjaro may be covered under their diabetes medication benefit. Zepbound may or may not be covered under their obesity or preventive care benefit, depending on the insurer and plan.
Patients without diabetes seeking weight loss: Zepbound is the on-label product. Prescribing Mounjaro for weight loss in someone without diabetes is off-label, which is legal but may create insurance coverage complications.
Medicare patients: Medicare Part D has historically excluded weight loss medications. Coverage of Zepbound under Medicare became possible for cardiovascular risk indications after a policy change, but coverage remains inconsistent across Part D plans.
Uninsured patients: The list prices are similar, Mounjaro and Zepbound list at approximately $1,000-1,100 per month. Eli Lilly offers savings programs for both. Compounded tirzepatide, available through telehealth programs, runs substantially less.
Off-Label Mounjaro Prescribing for Weight Loss
Before Zepbound’s approval, physicians routinely prescribed Mounjaro off-label for weight loss in patients without diabetes, because it was the only available tirzepatide formulation. After Zepbound’s approval, this practice became less clinically necessary but continues in some situations, particularly when Mounjaro is available and Zepbound is on backorder, or when a patient has existing Mounjaro coverage.
Whether prescribing Mounjaro versus Zepbound for weight loss affects patient outcomes: no, because the drug is pharmacologically identical.
Compounded Tirzepatide: Neither Brand
Compounded tirzepatide, prescribed through telehealth weight loss programs, uses neither the Mounjaro nor Zepbound formulation. It is tirzepatide manufactured by a compounding pharmacy from an API (active pharmaceutical ingredient) supplier. The same regulatory considerations that apply to compounded semaglutide apply here, quality depends on the compounding facility’s oversight, and the product is not FDA-approved.
The legal status of compounded tirzepatide has followed the same trajectory as compounded semaglutide, with availability linked to FDA shortage designations that change over time.
For a complete comparison of tirzepatide and semaglutide clinical trial data, see Tirzepatide vs. Semaglutide: What the Clinical Trials Actually Show. For understanding what tirzepatide’s dual mechanism involves, see What Is Tirzepatide and How Does It Work?
